FDA Class II Recall: Imprimis NJOF's Dexamethasone-Moxifloxacin-Ketorolac Vials Lacking Sterility Assurance
Imprimis NJOF, LLC has initiated a Class II nationwide recall of 38,060 vials of Dexamethasone-Moxifloxacin-Ketorolac intraocular injection due to a critical lack of sterility assurance. This event, originating from their Ledgewood, NJ facility, demands immediate action from procurement and regulatory teams to assess supply chain risks and ensure patient safety, given the product's direct ophthalmic application.
FDA Findings: Critical Sterility Assurance Lapses for Ophthalmic Product
Imprimis NJOF, LLC, operating from its facility at 1705 Route 46 Ste 6B, Ledgewood, NJ, United States, has initiated a Class II voluntary recall of 38,060 vials of Dexamethasone-Moxifloxacin-Ketorolac. This combination product, specifically formulated as a 1mg/mL, 0.5 mg/mL, and 0.4 mg/mL preservative-free solution in 1mL single-use vials for intraocular injection, is an Rx-only drug with NDC 71384-513-01. The critical reason for this recall, designated D-0514-2024, is a 'Lack of Assurance of Sterility.' This finding is particularly alarming for an intraocular product, where sterility is paramount to prevent severe patient harm. The affected lots include 23MAY008 (Exp. Date 5/1/24), 23OCT011 (Exp. Date 10/26/24), 23NOV035 (Exp. Date 12/6/24), and 24JAN024 (Exp. Date 1/14/25). Procurement directors must immediately identify if any of these specific lots are present within their inventory or distribution channels, as the recall's nationwide distribution pattern within the United States indicates widespread exposure. Regulatory affairs heads must recognize the severe implications of sterility failures for products administered directly into the eye, necessitating urgent risk mitigation strategies.
Operational Impact and Supply Chain Exposure for Imprimis NJOF, LLC
The recall initiated by Imprimis NJOF, LLC underscores significant operational challenges for the Ledgewood, NJ-based firm, particularly concerning its specialized ophthalmic compounding capabilities. While specific details regarding the facility's capacity, key markets beyond the U.S. domestic distribution, or its broader product portfolio are not publicly available, the nationwide distribution of 38,060 vials of Dexamethasone-Moxifloxacin-Ketorolac signifies a substantial market presence for this particular formulation. Supply chain VPs must conduct thorough internal audits to ascertain their exposure to this product and its raw material components, as the lack of sterility assurance points to potential systemic issues within the manufacturing process. The absence of readily available information on alternative suppliers for this specific compounded intraocular injection from public records means that procurement teams face an immediate challenge in identifying qualified backup sources. This situation necessitates a rapid assessment of internal capabilities or engagement with contract manufacturing organizations (CMOs) specializing in sterile ophthalmic products to ensure supply continuity and patient safety.
Mitigating Risks and Ensuring Sterility in Ophthalmic Formulations
The Class II classification of this recall, indicating that exposure may cause temporary or medically reversible adverse health consequences, is particularly critical for intraocular injections. Non-sterile products administered directly into the eye can lead to severe complications such as endophthalmitis, permanent vision loss, or even enucleation, highlighting the absolute necessity of robust sterility assurance. This event serves as a stark reminder for quality assurance and regulatory affairs heads across the industry to meticulously review their aseptic processing controls, environmental monitoring programs, and overall Good Manufacturing Practices (GMP) for sterile products. Broader industry trends, as evidenced by recent parallel events such as Pfizer's Class I recalls for glass particulate matter in injectables or Sandoz's Class II recall due to temperature excursion risks, demonstrate the diverse challenges in maintaining pharmaceutical product quality. While these specific issues differ from Imprimis NJOF, LLC's sterility concern, they collectively underscore the constant vigilance required in sterile manufacturing. This incident demands that all stakeholders in the ophthalmic pharmaceutical sector re-evaluate their risk management frameworks to prevent similar, potentially devastating, quality failures.
Regulatory Outlook and Strategic Procurement Considerations
The 'Ongoing' status of the Imprimis NJOF, LLC recall signifies that the FDA continues to monitor the firm's efforts to remove all affected Dexamethasone-Moxifloxacin-Ketorolac vials from the market and conduct effectiveness checks. While this was a voluntary, firm-initiated recall, the FDA retains the authority to conduct follow-up inspections and issue further enforcement actions, including a Warning Letter, if underlying GMP deficiencies are identified. Business development executives and procurement directors should immediately initiate comprehensive risk assessments for any existing or potential contracts with Imprimis NJOF, LLC, especially for sterile products. The absence of specific alternative suppliers for this compounded ophthalmic product in the public domain necessitates a proactive approach to supply chain resilience. Companies must prioritize the identification and qualification of secondary sources or explore internal development capabilities for critical ophthalmic compounds to mitigate future supply disruptions. This incident reinforces the imperative for robust supplier qualification processes and continuous monitoring of regulatory compliance to safeguard both patient safety and commercial interests in the highly regulated pharmaceutical sector.